Company Description
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer.
Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501.
Leap Therapeutics, Inc. has an option and license agreement with NovaRock, Adimab, and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand.
The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015.
Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.
| Country | United States |
| Founded | 2011 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 54 |
| CEO | Douglas Onsi |
Contact Details
Address: 47 Thorndike Street, Suite B1-1 Cambridge, Massachusetts 02141 United States | |
| Phone | 617 714 0360 |
| Website | leaptx.com |
Stock Details
| Ticker Symbol | LPTX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001509745 |
| CUSIP Number | 52187K101 |
| ISIN Number | US52187K2006 |
| Employer ID | 27-4412575 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Douglas E. Onsi J.D. | Chief Financial Officer, General Counsel, Treasurer and Secretary, President, Chief Executive Officer & Director |
| Augustine J. Lawlor | Chief Operating Officer |
| Dr. Cynthia A. Sirard M.D. | Chief Medical Officer |
| Dr. Jason S. Baum Ph.D. | Chief Scientific Officer |
| Mark O'Mahony | Chief Manufacturing Officer |
| Christine M. Granfield | Vice President and Head of Regulatory Affairs and Quality |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 31, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Oct 31, 2024 | SCHEDULE 13D/A | Filing |
| Sep 30, 2024 | 8-K | Current Report |
| Aug 12, 2024 | 8-K | Current Report |
| Aug 12, 2024 | 10-Q | Quarterly Report |
| Jul 8, 2024 | 8-K | Current Report |
| May 23, 2024 | EFFECT | Notice of Effectiveness |
| May 23, 2024 | 424B3 | Prospectus |
| May 16, 2024 | UPLOAD | Filing |
| May 16, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |